Xtx Topco LTD Selecta Biosciences Inc Transaction History

Xtx Topco LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.67 - $1.35 $32,919 - $66,329	-49,133 Reduced 57.81%	35,857 $24,000
Q3 2023 Nov 13, 2023	SELL	$1.02 - $1.23 $64,517 - $77,799	-63,252 Reduced 42.67%	84,990 $90,000
Q2 2023 Aug 14, 2023	BUY	$1.04 - $1.4 $154,171 - $207,538	148,242 New	148,242 $166,000
Q4 2022 Feb 14, 2023	SELL	$0.96 - $1.6 $4,745 - $7,908	-4,943 Reduced 2.58%	186,774 $211,000
Q3 2022 Nov 14, 2022	BUY	$1.33 - $2.6 $156,006 - $304,974	117,298 Added 157.62%	191,717 $314,000
Q2 2022 Aug 15, 2022	SELL	$0.67 - $1.4 $31,620 - $66,073	-47,195 Reduced 38.81%	74,419 $97,000
Q1 2022 May 13, 2022	BUY	$1.23 - $3.31 $108,257 - $291,326	88,014 Added 261.95%	121,614 $150,000
Q4 2021 Feb 11, 2022	BUY	$2.89 - $4.43 $97,104 - $148,848	33,600 New	33,600 $110,000
Q3 2021 Nov 12, 2021	SELL	$3.36 - $4.62 $107,194 - $147,391	-31,903 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$2.82 - $5.01 $89,966 - $159,834	31,903 New	31,903 $133,000

4.67M

Ticker SELB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 152,712,992
Market Cap $128M
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

Stay updated on Xtx Topco LTD with notifications on news.